[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.
3 Oct, 2021 | 23:02h | UTCCommentaries:
Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre
Covid antiviral pill can halve risk of hospitalization – BBC
Why Merck’s Covid-19 pill molnupiravir could be so important – Vox
Commentaries on Twitter
.@DrEricDing convinced many that stopping the #molnupiravir trial early for benefit was a good idea
But it was NOT
Large body of evidence suggests that stopping early for benefit biases the results: overestimates the benefits of the treatment #EBM https://t.co/b3tHEtliO0 https://t.co/LwuCgqcY0C pic.twitter.com/vyPWc0nd37
— Kari Tikkinen (@KariTikkinen) October 2, 2021
(thread – click for more)
?BREAKING—New oral anti-viral drug *molnupiravir* cuts risk of #COVID19 hospitalization and death **in HALF** in a randomized trial. Results so astounding that the trial is being stopped early, and Merck plans to apply for emergency authorization ASAP. ? https://t.co/g8JGNzvuRg pic.twitter.com/K1SwC3QFXS
— Eric Feigl-Ding (@DrEricDing) October 1, 2021